Circulating anticoagulants are endogenously produced substances that interfere with in vitro tests of coagulation like activated partial thromboplastin time (APTT), and cause prolongation of the clotting times. Evaluation of the abnormal APTT involving various factor assays and mixing studies may provide inconclusive and ambiguous results. Tissue thromboplastin inhibition test (TTIT) is one of the screening assays for detection of circulating anticoagulants. However, this test is influenced by the presence of unfractionated heparin (UFH) from concentrations 0.2 U/mL and higher. Since lowmolecular-weight heparins (LMWHs) are increasingly used for the prevention of thrombotic disorders and may replace UFH in the future, in this study the authors studied the influence of LMWHs on the performance of TTIT and compared the results with UFH. UFH and LMWHs showed a prolongation of TTIT in the concentration range of 0.25-1.0 U/mL. The marked prolongation of the TTIT with UFH and different LMWHs is in decreasing order of UFH > ardeparin > tinzaparin > dalteparin > enoxaparin. Patients with circulating anticoagulants who are given LMWHs may have false-positive results of TTIT and this influence should be kept in mind during patient management.
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Circulating anticoagulants are endogenously produced substances that interfere with various in vitro tests of coagulation (1, 2) . The association between circulating anticoagulants and systemic lupus erythematosus was first reported by Conley and Hartmann (3) in 1952. However, in the majority of cases these anticoagulants are found in individuals without any underlying disease. Patients with lupus anticoagulant very rarely have hemorrhagic complications and the evaluation of their abnormal activated partial thromboplastin time (APTT) may involve various factor assays and mixing studies providing inconclusive and ambiguous results. Effective laboratory evaluation of lupus anticoagulant patients is essential because this disease is associated with both arterial and venous thrombosis, as well as recurrent fetal loss and thrombocytopenia (4) (5) (6) . The subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis in 1995 recommended more than one screening assay to be performed before the presence of lupus anticoagulant can be ruled out (7) . One of the screening assays for lupus anticoagulant is tissue thromboplastin inhibition test (TTIT) described independently by Boxer et al. (8) and Schleider et al. (9) . This test is influenced by the factor deficiencies and the presence of unfractionated heparin (UFH) as well as by factor V, VIII, and IX inhibitors. In the presence of UFH at concentrations from 0.2 U/mL and higher, TTIT clotting time was prolonged (10-12). As laboratories occasionally encounter unsuspected heparinized specimens, they should be aware of the possible interference of these agents with assays designed to differentiate coagulation inhibitors (10). The low-molecular-weight heparins (LMWHs) are increasingly being used in the prevention and treatment of thrombotic disorders and most likely will replace UFH as the anticoagulant of choice. Therefore, it is crucial to evaluate the influence of LMWH on TTIT as this may show positivity in patients who are being screened for lupus anticoagulant by this test. In this ex vivo study, we have evaluated the influence of UFH and different LMWHs like ardeparin (MMW 6,000 D), tinzaparin (MMW 4,500 D), enoxaparin (MMW 4, 200 D) , and dalteparin (MMW 6,000 D) on TTIT.
MATERIALS AND METHODS

Materials
Enoxaparin was obtained from Aventis Pharmaceuticals (Rhone-Poulenc Rorer), Collegeville, PA; ardeparin was obtained from Wyeth-Ayerst, Philadelphia, PA; tinzaparin was obtained from Leo Pharmaceuticals, Copenhagen, Denmark; dalteparin was obtained from Pharmacia-Upjohn, Stockholm, Sweden; and unfractioned heparin was obtained from Sanofi-Synthelabo, Toulouse, France. Simplastin reagent and calcium chloride (0.025 M) were obtained from Organon Teknika, Durham, NC.
Sodium chloride (0.9%) was obtained from Baxter Healthcare Corporation, Deerfield IL; blood bank plasma (BBP) was obtained from the blood bank at Loyola University Medical Center, Maywood, IL; and the fibrometer was purchased from Becton Dickinson, New York, NY.
Methods
The UFH and LMWHs were reconstituted in saline to obtain a stock concentration of 100 U/mL. They were further diluted in saline to obtain working concentrations of 10 U/mL. The drugs were supplemented individually The diluted reagent was prewarmed at 37°C for at least 10 minutes before testing; calcium chloride (0.025 M) was also prewarmed at 37°C. Procedure of the 1TIT: 
RESULTS
The results of the TTIT for various dilutions with UFH and different LMWHs are given in Tables 1-3 UFH and all LMWHs tested showed concentration-dependent prolongation of TTIT clotting times. The most pronounced prolongation in TTIT is seen with UFH, ardeparin, and tinzaparin, followed by dalteparin and enoxaparin in decreasing order. UFH and all LMWH tested showed a prolongation of TTIT in the concentration range of 0.25-1.0 U/mL. However, at 0.125 U/mL the effect was very minimal. The prolongation was observed to be dilution dependent, with the longest clotting times with highest Simplastin dilutions. Figures 1-3 show the results of TTIT 1:50, 1:250, and 1:500 for UFH and different LM-WHs. There is a marked prolongation of the TTIT with UFH and LMWH in decreasing order of UFH > ardeparin > tinzaparin > dalteparin > enoxaparin. Differences between these four LMWHs were most obvious in TTIT assay performed with 1:500 Simplastin dilution. The re-sults of TTIT ( 1:500 dilution) ratio for UFH and various LMWHs supplemented in blood bank plasma are given in Table 4 . The results of TTIT ( 1:250 dilution) ratio for UFH and various LMWHs supplemented in blood bank plasma are given in Table 5 . The results of TTIT ( 1:50 dilution) ratio for UFH and various LMWHs supplemented in blood bank plasma are given in Table 6 .
DISCUSSION
The in vitro results of the supplementation of UFH and four different LMWHs in BBP show that the TTIT is prolonged in a concentration-dependent fashion. The strongest prolongation effect is seen with highest dilution ( 1:500) of the thromboplastin reagent. The concentration range of UFH and LMWH which influenced the TTIT was 0.25-1.0 U/mL. In earlier reports, it was shown in in vitro experiments that UFH influenced the TTIT in the range of >0.2 U/mL (10). Further, ex vivo studies will have to be carried out to determine whether the influence of LMWH on TTIT is in part due to the release of tissue factor pathway inhibitor (TFPI) or entirely a result of the drug itself. If there is an influence of TFPI on TTIT, it may not be detected in this in vitro study because of its low concentration. For that reason, TTIT should be performed on plasma samples obtained from patients receiving LMWH to appreciate the effect of TFPI on TTIT. TFPI could also be supplemented to the BBP along with LMWH to determine its effect on TTIT. Similarly, supplementation of antibodies against TFPI should show whether or not there is a shortening in the prolongation of TTIT compared to the plasma supplemented with TFPI and LMWH. Studies are in progress to determine the effects of TFPI on the performance of TTIT.
The results from this study have shown the prolongation of TTIT with UFH and various LMWHs are in the decreasing order of UFH > ardeparin > tinzaparin > dalteparin > enoxaparin. Interestingly, the highest prolongation of the TTIT values were seen with lowest anti-Xa :anti-IIa ratio. The best differentiation in doseresponse curve for different LMWHs was seen in highest thromboplastin dilutions. The effects of mean molecular weight and AXa:AIIa ratio of various LMWHs over TTIT are shown in Tables 7-9. As discussed, there is an inverse relationship between the TTIT values and the AXa:AIIa ratio. However, we did not observe any correlation between mean molecular weight of LMWH and TTIT results. The prolongation of the TTIT values with decreasing AXa:AIIa ratio suggests that there is an influence of anti-IIa of LMWH on the TTIT. It must be emphasized that these results were obtained in the in vitro studies. In the in vivo conditions, the AXa:AIIa ratios continually change due to differential pharmacokinetics of these agents and as a result, the tissue thromboplastin inhibition effects of these agents will also be influenced. This may contribute to the additional differences in the endogenous effects of these drugs. 
